FDAnews
www.fdanews.com/articles/88003-janssen-pharmaceutica-announces-collaboration-with-vertex-pharmaceuticals-to-develop-and-commercialize-vx-950-for-treatment-of-hepatitis-c

JANSSEN PHARMACEUTICA ANNOUNCES COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE VX-950 FOR TREATMENT OF HEPATITIS C

June 30, 2006

Johnson & Johnson announced today that Janssen Pharmaceutica N.V., a Johnson & Johnson company, has entered into a collaboration with Vertex Pharmaceuticals Incorporated to develop and commercialize Vertex's investigational hepatitis C virus (HCV) protease inhibitor, VX-950. Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=410842)